259 related articles for article (PubMed ID: 30514160)
21. Role of ethnicity in treating uterine fibroids with ulipristal acetate.
Murji A; Crosier R; Chow T; Ye XY; Shirreff L
Fertil Steril; 2016 Oct; 106(5):1165-1169. PubMed ID: 27336213
[TBL] [Abstract][Full Text] [Related]
22. Pregnancy Outcomes Following Ulipristal Acetate for Uterine Fibroids: A Systematic Review.
De Gasperis-Brigante C; Singh SS; Vilos G; Kives S; Murji A
J Obstet Gynaecol Can; 2018 Aug; 40(8):1066-1076.e2. PubMed ID: 30103881
[TBL] [Abstract][Full Text] [Related]
23. [The molecular mechanisms and morphological manifestations of leiomyoma reduction induced by selective progesterone receptor modulators].
Demura TA; Revazova ZV; Kogan EA; Adamyan LV
Arkh Patol; 2017; 79(3):19-26. PubMed ID: 28631712
[TBL] [Abstract][Full Text] [Related]
24. Ulipristal acetate for uterine fibroid-related symptoms.
Puchar A; Luton D; Koskas M
Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
[TBL] [Abstract][Full Text] [Related]
25. Ulipristal acetate before in vitro fertilization: efficacy in infertile women with submucous fibroids.
Morgante G; Centini G; Troìa L; Orvieto R; De Leo V
Reprod Biol Endocrinol; 2020 May; 18(1):50. PubMed ID: 32430027
[TBL] [Abstract][Full Text] [Related]
26. Role of vitamin D in uterine fibroid biology.
Brakta S; Diamond JS; Al-Hendy A; Diamond MP; Halder SK
Fertil Steril; 2015 Sep; 104(3):698-706. PubMed ID: 26079694
[TBL] [Abstract][Full Text] [Related]
27. Autophagy up-regulation by ulipristal acetate as a novel target mechanism in the treatment of uterine leiomyoma: an in vitro study.
Del Bello B; Marcolongo P; Ciarmela P; Sorbi F; Petraglia F; Luisi S; Maellaro E
Fertil Steril; 2019 Dec; 112(6):1150-1159. PubMed ID: 31843092
[TBL] [Abstract][Full Text] [Related]
28. EZH2 activates Wnt/β-catenin signaling in human uterine fibroids, which is inhibited by the natural compound methyl jasmonate.
Ali M; Stone D; Laknaur A; Yang Q; Al-Hendy A
F S Sci; 2023 Aug; 4(3):239-256. PubMed ID: 37182601
[TBL] [Abstract][Full Text] [Related]
29. Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids.
Szydłowska I; Marciniak A; Nawrocka-Rutkowska J; Rył A; Starczewski A
Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012826
[No Abstract] [Full Text] [Related]
30. The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids.
Pohl O; Zobrist RH; Gotteland JP
Reprod Sci; 2015 Apr; 22(4):476-83. PubMed ID: 25228633
[TBL] [Abstract][Full Text] [Related]
31. Ulipristal acetate versus placebo for fibroid treatment before surgery.
Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
[TBL] [Abstract][Full Text] [Related]
32. Vitamin D3 Inhibits Wnt/β-Catenin and mTOR Signaling Pathways in Human Uterine Fibroid Cells.
Al-Hendy A; Diamond MP; Boyer TG; Halder SK
J Clin Endocrinol Metab; 2016 Apr; 101(4):1542-51. PubMed ID: 26820714
[TBL] [Abstract][Full Text] [Related]
33. Management of symptomatic uterine fibroids after ulipristal acetate suspension and identification of high risk patients for surgery at 6-months of follow-up.
Nicolás I; Martínez-Zamora MÁ; Gracia M; Carrion A; Feixas G; Bernal L; Quintas L; Rius M; Castelo-Branco C; Carmona F
Gynecol Endocrinol; 2021 Sep; 37(9):831-835. PubMed ID: 34044726
[TBL] [Abstract][Full Text] [Related]
34. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Donnez J; Donnez O; Dolmans MM
Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
[TBL] [Abstract][Full Text] [Related]
35. Nutraceuticals in fibroid management after ulipristal acetate administration: An observational study on patients' compliance.
Tinelli A; Gustapane S; D'Oria O; Licchelli M; Panese G
Int J Gynaecol Obstet; 2022 Jan; 156(1):133-138. PubMed ID: 33797759
[TBL] [Abstract][Full Text] [Related]
36. Ulipristal acetate modulates the expression and functions of activin a in leiomyoma cells.
Ciarmela P; Carrarelli P; Islam MS; Janjusevic M; Zupi E; Tosti C; Castellucci M; Petraglia F
Reprod Sci; 2014 Sep; 21(9):1120-5. PubMed ID: 25001022
[TBL] [Abstract][Full Text] [Related]
37. Gene expression changes in uterine myomas in response to ulipristal acetate treatment.
Courtoy GE; Donnez J; Ambroise J; Arriagada P; Luyckx M; Marbaix E; Dolmans MM
Reprod Biomed Online; 2018 Aug; 37(2):224-233. PubMed ID: 29807764
[TBL] [Abstract][Full Text] [Related]
38. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment.
Courtoy GE; Donnez J; Marbaix E; Dolmans MM
Fertil Steril; 2015 Aug; 104(2):426-34.e1. PubMed ID: 26003270
[TBL] [Abstract][Full Text] [Related]
39. Effect on surgical decisions: Ulipristal acetate as key player in Belgian phase IV registration trial.
Verguts J; Godin PA; De Vree B; Donnez O; Cosyns S; Luyckx M; Nisolle M
Int J Gynaecol Obstet; 2019 Dec; 147(3):339-343. PubMed ID: 31502668
[TBL] [Abstract][Full Text] [Related]
40. Which is the destiny of ulipristal acetate for uterine fibroids? A commentary on the Italian medicines agency (AIFA) pronouncements.
Indraccolo U; Conzadori S; Greco P
Recenti Prog Med; 2019 Feb; 110(2):98-99. PubMed ID: 30843536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]